Cargando…

A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example

BACKGROUND: Assessment of the clinical significance of unclassified variants (UVs) identified in BRCA1 and BRCA2 is very important for genetic counselling. The analysis of co-segregation of the variant with the disease in families is a powerful tool for the classification of these variants. Statisti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Leila, Vreeswijk, Maaike P, Oldenburg, Rogier, van den Ouweland, Ans, Oosterwijk, Jan C, van der Hout, Annemarie H, Hoogerbrugge, Nicoline, Ligtenberg, Marjolijn, Ausems, Margreet G, van der Luijt, Rob B, Dommering, Charlotte J, Gille, Johan J, Verhoef, Senno, Hogervorst, Frans B, van Os, Theo A, Gómez García, Encarna, Blok, Marinus J, Wijnen, Juul T, Helmer, Quinta, Devilee, Peter, van Asperen, Christi J, van Houwelingen, Hans C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714556/
https://www.ncbi.nlm.nih.gov/pubmed/19563646
http://dx.doi.org/10.1186/1471-2407-9-211
_version_ 1782169687383080960
author Mohammadi, Leila
Vreeswijk, Maaike P
Oldenburg, Rogier
van den Ouweland, Ans
Oosterwijk, Jan C
van der Hout, Annemarie H
Hoogerbrugge, Nicoline
Ligtenberg, Marjolijn
Ausems, Margreet G
van der Luijt, Rob B
Dommering, Charlotte J
Gille, Johan J
Verhoef, Senno
Hogervorst, Frans B
van Os, Theo A
Gómez García, Encarna
Blok, Marinus J
Wijnen, Juul T
Helmer, Quinta
Devilee, Peter
van Asperen, Christi J
van Houwelingen, Hans C
author_facet Mohammadi, Leila
Vreeswijk, Maaike P
Oldenburg, Rogier
van den Ouweland, Ans
Oosterwijk, Jan C
van der Hout, Annemarie H
Hoogerbrugge, Nicoline
Ligtenberg, Marjolijn
Ausems, Margreet G
van der Luijt, Rob B
Dommering, Charlotte J
Gille, Johan J
Verhoef, Senno
Hogervorst, Frans B
van Os, Theo A
Gómez García, Encarna
Blok, Marinus J
Wijnen, Juul T
Helmer, Quinta
Devilee, Peter
van Asperen, Christi J
van Houwelingen, Hans C
author_sort Mohammadi, Leila
collection PubMed
description BACKGROUND: Assessment of the clinical significance of unclassified variants (UVs) identified in BRCA1 and BRCA2 is very important for genetic counselling. The analysis of co-segregation of the variant with the disease in families is a powerful tool for the classification of these variants. Statistical methods have been described in literature but these methods are not always easy to apply in a diagnostic setting. METHODS: We have developed an easy to use method which calculates the likelihood ratio (LR) of an UV being deleterious, with penetrance as a function of age of onset, thereby avoiding the use of liability classes. The application of this algorithm is publicly available http://www.msbi.nl/cosegregation. It can easily be used in a diagnostic setting since it requires only information on gender, genotype, present age and/or age of onset for breast and/or ovarian cancer. RESULTS: We have used the algorithm to calculate the likelihood ratio in favour of causality for 3 UVs in BRCA1 (p.M18T, p.S1655F and p.R1699Q) and 5 in BRCA2 (p.E462G p.Y2660D, p.R2784Q, p.R3052W and p.R3052Q). Likelihood ratios varied from 0.097 (BRCA2, p.E462G) to 230.69 (BRCA2, p.Y2660D). Typing distantly related individuals with extreme phenotypes (i.e. very early onset cancer or old healthy individuals) are most informative and give the strongest likelihood ratios for or against causality. CONCLUSION: Although co-segregation analysis on itself is in most cases insufficient to prove pathogenicity of an UV, this method simplifies the use of co-segregation as one of the key features in a multifactorial approach considerably.
format Text
id pubmed-2714556
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27145562009-07-24 A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example Mohammadi, Leila Vreeswijk, Maaike P Oldenburg, Rogier van den Ouweland, Ans Oosterwijk, Jan C van der Hout, Annemarie H Hoogerbrugge, Nicoline Ligtenberg, Marjolijn Ausems, Margreet G van der Luijt, Rob B Dommering, Charlotte J Gille, Johan J Verhoef, Senno Hogervorst, Frans B van Os, Theo A Gómez García, Encarna Blok, Marinus J Wijnen, Juul T Helmer, Quinta Devilee, Peter van Asperen, Christi J van Houwelingen, Hans C BMC Cancer Research Article BACKGROUND: Assessment of the clinical significance of unclassified variants (UVs) identified in BRCA1 and BRCA2 is very important for genetic counselling. The analysis of co-segregation of the variant with the disease in families is a powerful tool for the classification of these variants. Statistical methods have been described in literature but these methods are not always easy to apply in a diagnostic setting. METHODS: We have developed an easy to use method which calculates the likelihood ratio (LR) of an UV being deleterious, with penetrance as a function of age of onset, thereby avoiding the use of liability classes. The application of this algorithm is publicly available http://www.msbi.nl/cosegregation. It can easily be used in a diagnostic setting since it requires only information on gender, genotype, present age and/or age of onset for breast and/or ovarian cancer. RESULTS: We have used the algorithm to calculate the likelihood ratio in favour of causality for 3 UVs in BRCA1 (p.M18T, p.S1655F and p.R1699Q) and 5 in BRCA2 (p.E462G p.Y2660D, p.R2784Q, p.R3052W and p.R3052Q). Likelihood ratios varied from 0.097 (BRCA2, p.E462G) to 230.69 (BRCA2, p.Y2660D). Typing distantly related individuals with extreme phenotypes (i.e. very early onset cancer or old healthy individuals) are most informative and give the strongest likelihood ratios for or against causality. CONCLUSION: Although co-segregation analysis on itself is in most cases insufficient to prove pathogenicity of an UV, this method simplifies the use of co-segregation as one of the key features in a multifactorial approach considerably. BioMed Central 2009-06-29 /pmc/articles/PMC2714556/ /pubmed/19563646 http://dx.doi.org/10.1186/1471-2407-9-211 Text en Copyright ©2009 Mohammadi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mohammadi, Leila
Vreeswijk, Maaike P
Oldenburg, Rogier
van den Ouweland, Ans
Oosterwijk, Jan C
van der Hout, Annemarie H
Hoogerbrugge, Nicoline
Ligtenberg, Marjolijn
Ausems, Margreet G
van der Luijt, Rob B
Dommering, Charlotte J
Gille, Johan J
Verhoef, Senno
Hogervorst, Frans B
van Os, Theo A
Gómez García, Encarna
Blok, Marinus J
Wijnen, Juul T
Helmer, Quinta
Devilee, Peter
van Asperen, Christi J
van Houwelingen, Hans C
A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example
title A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example
title_full A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example
title_fullStr A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example
title_full_unstemmed A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example
title_short A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example
title_sort simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; brca1 and brca2 as an example
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714556/
https://www.ncbi.nlm.nih.gov/pubmed/19563646
http://dx.doi.org/10.1186/1471-2407-9-211
work_keys_str_mv AT mohammadileila asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vreeswijkmaaikep asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT oldenburgrogier asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vandenouwelandans asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT oosterwijkjanc asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanderhoutannemarieh asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT hoogerbruggenicoline asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT ligtenbergmarjolijn asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT ausemsmargreetg asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanderluijtrobb asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT dommeringcharlottej asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT gillejohanj asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT verhoefsenno asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT hogervorstfransb asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanostheoa asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT gomezgarciaencarna asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT blokmarinusj asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT wijnenjuult asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT helmerquinta asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT devileepeter asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanasperenchristij asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanhouwelingenhansc asimplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT mohammadileila simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vreeswijkmaaikep simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT oldenburgrogier simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vandenouwelandans simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT oosterwijkjanc simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanderhoutannemarieh simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT hoogerbruggenicoline simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT ligtenbergmarjolijn simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT ausemsmargreetg simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanderluijtrobb simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT dommeringcharlottej simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT gillejohanj simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT verhoefsenno simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT hogervorstfransb simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanostheoa simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT gomezgarciaencarna simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT blokmarinusj simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT wijnenjuult simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT helmerquinta simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT devileepeter simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanasperenchristij simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample
AT vanhouwelingenhansc simplemethodforcosegregationanalysistoevaluatethepathogenicityofunclassifiedvariantsbrca1andbrca2asanexample